Chemistry:Homatropine
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601006 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H21NO3 |
| Molar mass | 275.348 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Homatropine (Equipin, Isopto Homatropine) is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic (to temporarily paralyze accommodation), and as a mydriatic (to dilate the pupil).
The related chemical compound homatropine methylbromide (methylhomatropine) is a different medication. Homatropine is less potent than atropine and has a shorter duration of action. It is available as the hydrobromide salt. Homatropine is also given as an atropine substitute,[1] given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic (anti-AChase) administration.
Homatropine hydrobromide is on the World Health Organization's List of Essential Medicines.[2]
Side effects
- Blurred vision
- Sensitivity to light
Contraindications
- Untreated glaucoma
- Myasthenia gravis
- Severe heart failure
- Thyrotoxicosis
References
- ↑ "Megacolon associated with administration of an anticholinergic drug in a patient with ulcerative colitis". The American Journal of Digestive Diseases 9 (4): 268–274. April 1964. doi:10.1007/bf02232133. PMID 14142388.
- ↑ The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.
 |  |
